News & Views
Installation adds Scale-Up Capability for Antibody Production
May 15 2017
BioInvent International AB, developers of immuno-regulatory antibodies for cancer treatment is upgrading and expanding its drug manufacturing operations with a full line of Merck’s Mobius® single-use bioreactors, adding 3L, 50L, 200L and 1000L bioreactors to its upstream facility in Lund, Sweden.
"Our complete portfolio of single-use technologies addresses the needs of both emerging biopharmaceutical companies and established drug developers like BioInvent as they seek to increase productivity," said Udit Batra, Member of the Merck Executive Board and CEO of the life science business sector of Merck. "We are providing a full range of bioreactors, services and support which will help BioInvent accelerate innovative therapeutics through the development pipeline."
The upgrade of the BioInvent facility to include a 1000-liter single-use bioreactor will allow the company to meet production requirements for both its own novel antibody development projects and also those of customers they serve around the world.
"BioInvent has been discovering and manufacturing antibodies for more than 30 years, and when we decided to upgrade our single-use production facility, we established very demanding requirements," said Kristoffer Rudenholm Hansson, vice president of Technical Operations at BioInvent. "Merck's single-use bioreactors most effectively addressed our current and future needs with a fully scalable system."
Digital Edition
International Labmate 49.6 - Sept 2024
September 2024
Chromatography Articles - HPLC gradient validation using non-invasive flowmeters Mass Spectrometry & Spectroscopy Articles - From R&D to QC, making NMR accessible for everyone: Putting NMR...
View all digital editions
Events
Sep 29 2024 Singapore
Oct 06 2024 Liverpool, UK
Oct 08 2024 Gothenburg, Sweden
Oct 09 2024 Birmingham, UK
Oct 09 2024 NEC, Birmingham, UK